Results 181 to 190 of about 908,554 (203)

NTRK Fusions in Xanthogranuloma, a Clinicopathologic and Molecular Analysis of 23 Cases.

American Journal of Surgical Pathology
Xanthogranuloma is the most common category of histiocytic neoplasia, with a range of clinical behaviors from solitary cutaneous lesions to multiple cutaneous lesions and less frequent cases with evolution to disseminated disease.
B. Umphress, Aofei Li, Matthew Kuhar, R. Kowal, A. Alomari, LeeAnn Baldridge, Anthony J Ross, Simon J Warren   +7 more
semanticscholar   +1 more source

Abstract A021: Standardized Oncogenic Classification Guidance of Critical Diagnostic and Therapeutic markers in pediatric cancers: NTRK fusions

Cancer Research
Gene fusions involving neurotrophic receptor tyrosine kinase genes (NTRK1, NTRK2, & NTRK3) are well-established oncogenic drivers and serve as critical diagnostic and therapeutic markers in pediatric hematologic malignancies and solid tumors.
J. Saliba, Shivani Golem, Arpad M. Danos, Laura B. Corson, Morteza Seifi, J. C. Santiago, Emma G. Sullivan, Scott Myrand, Elan Hahn, Valentina Nardi, Theodore W. Laetsch, Marilyn M. Li, O. Griffith, M. Griffith, G. Raca, Larissa V. Furtado, Angshumoy Roy, A. Church   +17 more
semanticscholar   +1 more source

Abstract 6187: ICP-723 is a potent pan-TRK Inhibitor with robust anti-tumor activities against wild-type and acquired drug-resistant mutations of NTRK fusions

Cancer Research, 2022
Background: Somatic oncogenic fusions of NTRK with other genes, such as ETV6, LMNA, TPM3, PAN3, etc. occur in a wide range of adult and pediatric tumors.
Ruixia Liang, Chao Zhou, Yingrui Han, P. Lu, Charles Ying Wang, Zuopeng Wang, Richard Liu, Norman Kong, Jason Zhang, J. J. Cui, D. Ouyang   +10 more
semanticscholar   +1 more source

173P Entrectinib in NTRK fusion-positive (NTRK-fp) breast cancer

2022
BackgroundFusions in the neurotrophic tyrosine receptor kinase (NTRK) genes act as oncogenic drivers in many solid tumours, including secretory and non-secretory breast cancers. In the phase 2 STARTRK-2 clinical trial (NCT02568267), entrectinib (a TRK inhibitor with CNS activity) induced objective responses in 83.3% of patients (pts) with NTRK-fp ...
Lu, J., Blakely, C.M., Barve, M., Chung, C.H., Waqar, S.N., Hu, X., Delord, J-P., Krzakowski, M.J., Yonemori, K., Chen, D.T., Klingbiel, D., Heinzmann, S., Le Tourneau, C.   +12 more
openaire   +1 more source

Identification of NTRK fusions in pediatric mesenchymal tumors

Pediatric Blood & Cancer, 2017
AbstractBackgroundNTRK fusions are known oncogenic drivers and have recently been effectively targeted by investigational agents in adults. We sought to assess the frequency of NTRK fusions in a large series of pediatric and adolescent patients with advanced cancers.ProcedureGenomic profiles from 2,031 advanced cancers from patients less than 21 years ...
Dean, Pavlick, Alexa B, Schrock, Denise, Malicki, Philip J, Stephens, Dennis J, Kuo, Hyunah, Ahn, Brian, Turpin, Justin M, Allen, Mark, Rosenzweig, Kamran, Badizadegan, Jeffrey S, Ross, Vincent A, Miller, Victor, Wong, Siraj M, Ali   +13 more
openaire   +2 more sources

Emerging Targeted Therapy for Tumors with NTRK Fusion Proteins

Clinical Cancer Research, 2018
Abstract The oncogenesis-promoting role of chromosomal rearrangements for several hematologic and solid malignancies is well recognized. However, identifying targetable, actionable, and druggable chromosomal rearrangements remains a challenge. Targeting gene fusions and chromosomal rearrangements is an effective strategy in treating gene
Ed S, Kheder, David S, Hong
openaire   +2 more sources

NTRK fusion genes in thyroid cancer

Endocrine Abstracts, 2021
Barbora Pekova, Vlasta Sykorova, Karolina Mastnikova, Eliska Vaclavikova, Jitka Moravcova, Vlcek Petr, Petr Lastuvka, Milos Taudy, Rami Cisel, Petr Bavor, Daniela Kodetova, Martin Kodetova, Jana Drozenova, Jaromir Kodetova, Petr Hrabal, Josef Vcelak, Bela Bendlova   +16 more
openaire   +1 more source

How Sensitive is Pan-TRK Immunohistochemistry for Detecting NTRK Fusions in Papillary Thyroid Carcinoma?

Modern Pathology, 2023
Jen-Fan Hang, Yu-cheng Lee
semanticscholar   +1 more source

Cost-effectiveness of NTRK testing strategies for detecting NTRK fusions in solid tumors in China.

Journal of Clinical Oncology
3131 Background: Neurotrophic tyrosine receptor kinase (NTRK) gene fusions are oncogenic drivers in many solid tumors. With the inclusion of the targeted drug Entrectinib in China's national reimbursement drug list, the demand for NTRK testing has also increased.
Jian Wang, Lifeng Wang, Shenglei Li, Wen Chen   +3 more
openaire   +1 more source

Pan-TRK immunohistochemistry to optimize the detection of NTRK fusions: removing the hay when looking for the needle.

Modern Pathology, 2023
E. Conde, S. Hernandez, M. Alonso, F. Lopez-Rios   +3 more
semanticscholar   +1 more source